全文获取类型
收费全文 | 179697篇 |
免费 | 7676篇 |
国内免费 | 411篇 |
专业分类
耳鼻咽喉 | 2481篇 |
儿科学 | 5108篇 |
妇产科学 | 4104篇 |
基础医学 | 25837篇 |
口腔科学 | 7025篇 |
临床医学 | 10630篇 |
内科学 | 39379篇 |
皮肤病学 | 4881篇 |
神经病学 | 14420篇 |
特种医学 | 4488篇 |
外国民族医学 | 1篇 |
外科学 | 20742篇 |
综合类 | 811篇 |
一般理论 | 30篇 |
预防医学 | 21454篇 |
眼科学 | 4538篇 |
药学 | 13981篇 |
中国医学 | 808篇 |
肿瘤学 | 7066篇 |
出版年
2023年 | 937篇 |
2022年 | 698篇 |
2021年 | 3086篇 |
2020年 | 1792篇 |
2019年 | 3324篇 |
2018年 | 5560篇 |
2017年 | 3544篇 |
2016年 | 3512篇 |
2015年 | 4005篇 |
2014年 | 4540篇 |
2013年 | 6640篇 |
2012年 | 11354篇 |
2011年 | 12064篇 |
2010年 | 5996篇 |
2009年 | 4398篇 |
2008年 | 9688篇 |
2007年 | 10315篇 |
2006年 | 9765篇 |
2005年 | 9275篇 |
2004年 | 8595篇 |
2003年 | 8001篇 |
2002年 | 7547篇 |
2001年 | 5234篇 |
2000年 | 5772篇 |
1999年 | 4396篇 |
1998年 | 783篇 |
1992年 | 2351篇 |
1991年 | 2120篇 |
1990年 | 2053篇 |
1989年 | 1781篇 |
1988年 | 1679篇 |
1987年 | 1579篇 |
1986年 | 1604篇 |
1985年 | 1507篇 |
1984年 | 1073篇 |
1983年 | 936篇 |
1979年 | 1247篇 |
1978年 | 825篇 |
1977年 | 801篇 |
1976年 | 753篇 |
1975年 | 891篇 |
1974年 | 1135篇 |
1973年 | 1194篇 |
1972年 | 1129篇 |
1971年 | 1097篇 |
1970年 | 1024篇 |
1969年 | 1102篇 |
1968年 | 1140篇 |
1967年 | 991篇 |
1966年 | 896篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Molnár B. Aroca S. Dobos A. Orbán K. Szabó J. Windisch P. Stähli A. Sculean A. 《Clinical oral investigations》2022,26(12):7135-7142
Clinical Oral Investigations - To evaluate t he long-term outcomes following treatment of RT 1 multiple adjacent gingival recessions (MAGR) using the modified coronally advanced tunnel (MCAT) with... 相似文献
2.
3.
Vilar-Compte Mireya Gaitán-Rossi Pablo Félix-Beltrán Lucía Bustamante Arturo V. 《Journal of immigrant and minority health / Center for Minority Public Health》2022,24(1):65-77
Journal of Immigrant and Minority Health - COVID-19 has disproportionally affected underrepresented minorities (URM) and low-income immigrants in the United States. The aim of the study is to... 相似文献
4.
5.
6.
María C. Lanuza-López Sandra G. Martínez-Garza Jesús F. Solórzano-Vázquez Daniela Paz-Cervantes Claudia González-Ortega Israel Maldonado-Rosas 《Gynecological endocrinology》2020,36(9):829-834
AbstractOocyte maturation defect is a challenging situation in the management of infertility, the etiology may be related to endocrine causes, protocols used in ovarian stimulation, oocyte intrinsic defects or procedures in embryology laboratory. We report three Mexican females in treatment for primary infertility with non-mature oocytes after ovary stimulation and oocyte capture in whom a genetic diagnosis of TUBB8-oocyte maturation defect was revealed by exome sequencing. Two couples achieved pregnancies though oocyte donation after establishing the genetic etiology. Our results expand the role of TUBB8-disorders in patients of non-Asian ethnicity. Oocyte maturation defects of monogenic origin are a growing group of disorders that endocrinologists and reproductive medicine specialists should be aware in order to provide referral to genetics for establish a correct and opportune diagnosis. 相似文献
7.
8.
9.
10.
Sarina A. Piha-Paul Do-Youn Oh Makoto Ueno David Malka Hyun Cheol Chung Adnan Nagrial Robin K. Kelley Willeke Ros Antoine Italiano Kazuhiko Nakagawa Hope S. Rugo Filippo de Braud Andrea Iolanda Varga Aaron Hansen Hui Wang Suba Krishnan Kevin G. Norwood Toshihiko Doi 《International journal of cancer. Journal international du cancer》2020,147(8):2190-2198
We present data from patients with advanced biliary tract cancer (BTC) receiving pembrolizumab in the KEYNOTE-158 (NCT02628067; phase 2) and KEYNOTE-028 (NCT02054806; phase 1b) studies. Eligible patients aged ≥18 years from both studies had histologically/cytologically confirmed incurable BTC that progressed after standard treatment regimen(s), measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, Eastern Cooperative Oncology Group performance status 0/1, and no prior immunotherapy. Programmed death ligand 1 (PD-L1)-positive tumors were required for eligibility in KEYNOTE-028 only. Patients received pembrolizumab 200 mg every three weeks (KEYNOTE-158) or 10 mg/kg every two weeks (KEYNOTE-028) for ≤2 years. Primary efficacy endpoint was objective response rate (ORR) by RECIST v1.1. Response assessed by independent central review is reported. KEYNOTE-158 enrolled 104 patients and KEYNOTE-028 enrolled 24 patients. Median (range) follow-up was 7.5 months (0.6-34.3) in KEYNOTE-158 and 5.7 months (0.6-55.4) in KEYNOTE-028. In KEYNOTE-158, ORR was 5.8% (6/104; 95% CI, 2.1%-12.1%); median duration of response (DOR) was not reached (NR) (range, 6.2-26.6+ months). Median (95% CI) OS and PFS were 7.4 (5.5-9.6) and 2.0 (1.9-2.1) months. Among PD-L1-expressers (n = 61) and PD-L1-nonexpressers (n = 34), respectively, ORR was 6.6% (4/61) and 2.9% (1/34). In KEYNOTE-028, ORR was 13.0% (3/23; 95% CI, 2.8%-33.6%); median DOR was NR (range, 21.5-53.2+ months). Median (95% CI) OS and PFS were 5.7 (3.1-9.8) and 1.8 (1.4-3.1) months. Grade 3 to 5 treatment-related adverse events occurred in 13.5% of patients in KEYNOTE-158 (no grade 4; grade 5 renal failure, n = 1) and 16.7% in KEYNOTE-028 (no grade 4/5). In summary, pembrolizumab provides durable antitumor activity in 6% to 13% of patients with advanced BTC, regardless of PD-L1 expression, and has manageable toxicity. 相似文献